secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001193125-26-015592
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies secures €166.7M from full exercise of warrants after positive VITESSE trial
--------------------------------------------------------------------------------

- €166.7M gross proceeds from full exercise of ABSA Warrants (34.1M) and BS Warrants (71.0M) issued March 2025.
- Proceeds to fund BLA submission and U.S. launch preparations for VIASKIN Peanut patch in children 4-7 years if approved.
- Company expects to be funded for at least 12 months, including through potential commercial launch.
- Exercise triggered by positive VITESSE Phase 3 topline results announced December 16, 2025; no warrants remain outstanding.
- 59.7M new ordinary shares issued; additional pre-funded warrants may access up to 154M new shares in future.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526015592/0001193125-26-015592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312526015592/d74681d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-015592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer